1 / 9

Global Hepatitis B Vaccines Market 2014-2018

About Hepatitis B Vaccines Hepatitis B is an inflammatory condition that occurs due to infection by hepatitis B virus. Hepatitis B virus is an enveloped virus that belongs to the family of hepadnavirus. It contains a circular genome with partially double-stranded DNA. The virus interferes with the normal functioning of the liver cells. Following the viral infection, the immune system is activated against virus and hepatocytes infected with viruses. This, in turn, leads to the inflammation of the liver. Extra-hepatic manifestations of hepatitis B include polyarteritis nodosa, Gianotti-Crosti syndrome, transient serum sickness-like syndrome, and membranous glomerulonephritis. Perinatal transmission of hepatitis B virus is the most common mode of infection spread. Age of a person at the time of infection and infecting dose of virus are important factors that determine the severity of acute or chronic hepatitis B. Most of the patients suffering from acute hepatitis B recover spontaneously without significant consequences. The chronic form of infection, in some cases, can progress up to cirrhosis and liver cancer. Hepatitis B infection can be prevented by immunization with hepatitis B vaccines. Get full access of the report at: http://www.researchbeam.com/global-hepatitis-b-vaccines-2014-2018-market

Alexus
Download Presentation

Global Hepatitis B Vaccines Market 2014-2018

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Hepatitis B Vaccines Market 2014-2018 Publish By: Technovia Toll Free: +1 (855) 711-1555 Email: sales@researchbeam.com

  2. Report Overview About Hepatitis B Vaccines Hepatitis B is an inflammatory condition that occurs due to infection by hepatitis B virus. Hepatitis B virus is an enveloped virus that belongs to the family of hepadnavirus. It contains a circular genome with partially double-stranded DNA. The virus interferes with the normal functioning of the liver cells. Following the viral infection, the immune system is activated against virus and hepatocytes infected with viruses. This, in turn, leads to the inflammation of the liver. Extra-hepatic manifestations of hepatitis B include polyarteritisnodosa, Gianotti-Crosti syndrome, transient serum sickness-like syndrome, and membranous glomerulonephritis. Perinatal transmission of hepatitis B virus is the most common mode of infection spread. Age of a person at the time of infection and infecting dose of virus are important factors that determine the severity of acute or chronic hepatitis B. Most of the patients suffering from acute hepatitis B recover spontaneously without significant consequences. The chronic form of infection, in some cases, can progress up to cirrhosis and liver cancer. Hepatitis B infection can be prevented by immunization with hepatitis B vaccines. TechNavio'sanalysts forecast the Global Hepatitis B Vaccines market to grow at a CAGR of 4.00 percent over the period 2013-2018.

  3. Report Overview Key Regions • Americas • APAC • EMEA Key Vendors • GlaxoSmithKline • Merck • Sanofi Pasteur Other Prominent Vendors • Dynavax Technologies • Janssen Pharmaceuticals • LG Life Sciences • Kaketsuken • Shenzhen Kangtai Biological Products Market Driver • Increased Awareness about Hepatitis B Infection and Prevention • For a full, detailed list, view our report Get full access of the report at: http://www.researchbeam.com/global-hepatitis-b-vaccines-2014-2018-market

  4. Report Overview Market Challenge • Inadequate Vaccine Coverage • For a full, detailed list, view our report Market Trend • Combination Vaccines • For a full, detailed list, view our report Key Questions Answered in this Report • What will the market size be in 2018 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors?

  5. Table Of Content 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 03.1 Market Overview 03.2 Product Offerings 04. Market Research Methodology 04.1 Market Research Process 04.2 Research Methodology 05. Disease Overview 05.1 Hepatitis B: Acute and Chronic Infection

  6. Table Of Content 05.2 Hepatitis B: Geographical Distribution 05.3 Hepatitis B: Estimated National Immunization Coverage 05.3.1 Hepatitis B Birth Dose Vaccine 05.3.2 Third Dose of Hepatitis B Vaccine 05.4 Chronic Disease Prone Individuals for Hepatitis B 05.5 Hepatitis B: Diagnosis 05.5.1 Serological Markers 05.5.2 Hepatitis B Serologic Test Interpretation 06. Introduction 07. Market Landscape

  7. List of Exhibits Exhibit 1: Market Research Methodology Exhibit 2: Pathway of Hepatitis B Progression Exhibit 3: Number of Hepatitis B Birth Doses Administered in WHO Regions Exhibit 4: Trend of Hepatitis B Birth Doses Administered in WHO Regions 2000-2013 Exhibit 5: Percentage Share of Different Regions in 2013 Exhibit 6: Number of Third Doses of Hepatitis B Administered in WHO Regions Exhibit 7: Trend of Third Doses of Hepatitis B Administered in WHO Regions 2000-2013 Exhibit 8: Percentage Share of Different Regions in 2013 Exhibit 9: Comparison of Third Dose and Birth Dose in 2013 in WHO Regions Exhibit 10: Disease Progression of Hepatitis B

  8. List of Exhibits Exhibit 11: Significance of Serological Markers Exhibit 12: Interpretation of Serological Markers Exhibit 13: Global Hepatitis B Vaccines Market 2013-2018 (US$ million) Exhibit 14: Global Hepatitis B Vaccines Market Segmentation by Composition Exhibit 15: Dosage Regimen of Engerix-B Exhibit 16: Dosage Regimen of Fendrix Exhibit 17: Dosage Regimen of Recombivax HB Exhibit 18: Dosage Regimen of Infanrixhexa To make an enquiry before purchasing the report, visit at: http://www.researchbeam.com/global-hepatitis-b-vaccines-2014-2018-market/purchase-enquiry

  9. Contact Us Direct: +1 (617) 674-4143 Toll Free: +1 (855) 711-1555 Fax: +1 (855) 550-5975 Web: www.researchbeam.com Email: sales@researchbeam.com Deep 5320 SW Macadam Avenue, Suite 100, Portland, OR 97239 United States

More Related